Page 17 - Viral Vector News Today

Researchers recently developed an immunodiagnostic T cell assay to classify T cell immune responses of the subjects based on their coronavirus disease 2019 infection and vaccination history.

/PRNewswire/ -- Expression Therapeutics, Inc., a fully integrated clinical stage biotechnology company developing novel cell and gene therapies celebrates the...

/PRNewswire/ -- Expression Therapeutics, Inc., a fully integrated clinical stage biotechnology company developing novel cell and gene therapies celebrates the...

Last updated: December 8, 2021 at 3:40 p.m. Book a COVID-19 vaccine appointment using the Province’s registration system or by calling 1-833-943-3900 (TTY 1-866-797-0007). Book an Appointment Children 5 to 11 years old are eligible for the COVID-19 vaccine. Find out about Toronto Kids Vaccine Day on December 12 at Scotiabank Arena. Learn about third doses […]

CDMO earnings call for the period ending October 31, 2021.

Researchers collaborated to address these evidence gaps by initiating a web-based prospective study of adults diagnosed with multiple myeloma to determine the immune response to the first and second dose of the COVID-19 vaccine.

Viral Vector & Plasmid DNA Manufacturing Market: An Exclusive Study on Upcoming Trends and Growth Opportunities

Viral Vector & Plasmid DNA Manufacturing Market: An Exclusive Study on Upcoming Trends and Growth Opportunities

Merck KGgA and subsidiary MilliporeSigma have completed work on their second Carlsbad, California-based facility.

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the success of the Oxford-AstraZeneca vaccine against SARS-CoV-2 to develop a vaccine to treat cancer.